# Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

> **NCT02730195** · PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 9 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

## Interventions

- **DRUG:** Pioglitazone
- **DRUG:** Tyrosine Kinase Inhibitor (TKI)

## Key facts

- **NCT ID:** NCT02730195
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02730195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02730195, "Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02730195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*